| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2011-02-03 | lixisenatide (once daily GLP-1 receptor agonist) | acute myocardial infarction | 3 | Sanofi -Aventis (France) Zealand Pharma (Denmark) | Cardiovascular diseases |
| 2011-02-02 | AS1413 (amonafide) | high-grade brain tumors | 3 | Antisoma (UK) | Cancer Oncology |
| 2011-02-01 | Imvamune® | smallpox in individuals suffering from atopic dermatitis |
2 | Bavarian Nordic (Denmark) | Infectious diseases |
| 2011-01-31 | Tarceva® (erlotinib) | advanced, metastatic pancreatic cancer in patients refractory to 1st line gemcitabine treatment | 3 | Roche (Switzerland) | Cancer Oncology |
| 2011-01-28 | Almorexant | primary insomnia |
3 | Actelion (Switzerland)GSK (UK) | CNS diseases - Neurological diseases |
| 2011-01-28 | masitinib | secondary acute myeloid leukaemia | 3 | AB Science (France) | Cancer Oncology |
| 2011-01-27 | BSI-201 (iniparib) | metastatic triple-negative breast cancer | 3 | Sanofi-Aventis (France) | CancerOncology |
| 2011-01-27 | Cytotect® (anti-cytomegalovirus hyperimmunoglobulin) | cytomegalovirus infection | 3 | Biotest (Germany) | Infectious diseases |
| 2011-01-27 | AM-101 | inner ear tinnitus | 1-2 | Auris Medical (Switzerland) | Otorhinolaryngology |
| 2011-01-24 | SBG | wound healing |
preclinical | Biotec Pharmacon (Norway) | |
| 2011-01-24 | GSK’436 | advanced or metastatic melanoma with a BRAF V600 mutation | 3 | GSK (UK) | Cancer Oncology |
| 2011-01-24 | GSK’212 | advanced/metastatic melanoma focuses on patients with BRAF V600 mutation who have had no more than one prior regimen of chemotherapy and no prior BRAF inhibitor treatment | 3 | GSK (UK) | Cancer Oncology |
| 2011-01-20 | Erbitux (cetuximab) | KRAS wild-type metastatic colorectal cancer (mCRC) |
2 | Merck Serono, a Merck KGaA company (Germany) | Cancer - Oncology |
| 2011-01-20 | zicronapine (Lu 31-130) | schizophrenia |
3 | Lundbeck (Denmark) | Mental diseases - CNS diseases |
| 2011-01-19 | RG7204 The product is being co-developed under a 2006 license and collaboration agreement between Roche and Plexxikon. | BRAF V600 mutation-positive metastatic melanoma. | 3 | Roche (Switzerland) | CancerOncology |
| 2011-01-19 | zanamivir | influenza | 3 | GSK (UK) | Infectious diseases |
| 2011-01-18 | VEGF Trap-Eye (aflibercept ophthalmic solution) | choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia |
3 | Bayer HealthCare (Germany) Regeneron Pharmaceuticals (USA) | Ophtalmology |
| 2011-01-17 | talactoferrin | severe sepsis | 2 | Agennix (Germany) | Infectious diseases |
| 2011-01-12 | MEDI-565 (MT111) | advanced gastrointestinal cancer | 1 | Medimmune (USA) Micromet (USA-Germany) | Cancer - Oncology |
| 2011-01-12 | Vyvanse® (lisdexamfetamine dimesylate) | Excessive Daytime Sleepiness |
Shire (UK-USA) | CNS diseases |
